Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The company defends its cancer strategy, and says it's not a me-too developer.